ClinicalTrials.gg
CompletedNCT03070119Updated Aug 29, 2025Results posted

Long-Term Evaluation of BIIB067 (Tofersen)

A Phase 3 interventional study of Tofersen in ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation, sponsored by Biogen. Completed at 30 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-29.

Sponsored by Biogen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
139
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of the study is to evaluate the long-term safety and tolerability of BIIB067 (tofersen) in participants with amyotrophic lateral sclerosis (ALS) and confirmed superoxide dismutase 1 (SOD1) mutation. The secondary objectives are to evaluate the pharmacokinetic (PK), pharmacodynamic (PD), biomarker effects, and efficacy of BIIB067 administered to participants with ALS and a confirmed SOD1 mutation.

02

Conditions studied

  • ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation
03

In context

Lead sponsor

Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.

Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Must have diagnosis of superoxide dismutase 1-amyotrophic lateral sclerosis (SOD1-ALS), and must have completed the End of Study Visit for either Parts A, B, or C of Study 233AS101 (NCT02623699) (i.e., were not withdrawn).
  • If taking riluzole, participant must be receiving a stable dose for ≥30 days prior to Day 1.
  • If taking edaravone, participant must have initiated edaravone ≥60 days (2 treatment cycles) prior to Day 1. Edaravone may not be administered on dosing days during this study.
  • Medically able to undergo the study procedures, and to adhere to the visit schedule at the time of study entry, as determined by the Investigator.
  • For female participants of must agree to practice effective during the study and be willing and able to continue contraception for 5 months after their last dose of study treatment.
  • Participants from Study 233AS101 Parts A and B must have a ≥16 weeks between the last dose of study treatment received in Study 233AS101 and the first dose of BIIB067 received in the current Study 233AS102.

Key Exclusion Criteria:

  • History of allergies to a broad range of anesthetics.
  • Presence of risk for increased or uncontrolled bleeding and/or risk of bleeding that is not managed optimally and could place a participant at an increased risk for bleeding during or after a Lumbar Puncture (LP) procedure. These risks could include, but are not limited to, anatomical factors at or near the LP site (e.g., vascular abnormalities, neoplasms, or other abnormalities) and underlying disorders of the coagulation cascade, function, or platelet count (e.g., hemophilia, Von Willebrand's disease, liver disease).
  • Presence of an implanted shunt for the drainage of CSF or an implanted central nervous system (CNS) catheter.
  • Prior or current treatment with small interfering ribonucleic acid (RNA), stem cell therapy, or gene therapy.
  • Treatment with another drug, biological agent (excluding BIIB067), or device within 1 month or 5 half-lives of study agent, whichever is longer.
  • Current or anticipated need, in the opinion of the Investigator, of a diaphragm pacing system (DPS) during the study period.
  • Current or recent (within 1 month) use, or anticipated need, in the opinion of the Investigator, of copper (II) (diacetyl-bis(N4-methylthiosemicarbazone)) or pyrimethamine.
  • Female participants who are pregnant or currently breastfeeding.
  • Current enrollment in any other interventional study.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
139 participants (actual)

Study arms

  • Experimental
    BIIB067

    Participants who have completed Parts A, B, or C of study 233AS101 will be placed in this arm.

    Drug: Tofersen

Interventions

  • Participants will receive a loading dose regimen followed by maintenance dosing.

    Also known as: BIIB067, QALSODY

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious AEs (TESAEs)

    An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE is any untoward medical occurrence that at any dose results in death, life-threatening event, requires inpatient hospitalization, significant disability/incapacity or congenital anomaly. TEAEs were defined as any AEs or SAE with an onset date and time that was on or after the first dose of study drug, or any pre-existing condition that worsened in severity after the first dose of study drug.

    Time frame: From first dose of the study drug in the current study up to end of follow-up period (up to Week 364)

Secondary outcomes

  1. Plasma Concentration of BIIB067

    Time frame: Week 4

  2. Concentration of BIIB067 in Cerebrospinal Fluid (CSF)

    Time frame: Week 4

  3. 233AS101 and 233AS102 Integrated Summary of Efficacy (ISE): Total CSF Superoxide Dismutase 1 (SOD1) Protein Ratio to Baseline

    This outcome measure was not a standalone analysis for 233AS102. Analysis was performed on the data collected from both 233AS101 and 233AS102 studies. This is reported as a part of the final integrated analyses. Baseline is defined as the Day 1 of 233AS101 Part C. Data has been reported for Weeks 52, 104 and 148 from the 233AS101 Part C baseline.

    Time frame: Baseline, Weeks 52, 104 and 148

  4. 233AS101 and 233AS102 ISE: Neurofilament Light Chain (NfL) Plasma Concentration Ratio to Baseline

    This outcome measure was not a standalone analysis for 233AS102. Analysis was performed on the data collected from both 233AS101 and 233AS102 studies. This is reported as a part of the final integrated analyses. Baseline is defined as the Day 1 of 233AS101 Part C. Data has been reported for Weeks 52, 104 and 148 from the 233AS101 Part C baseline.

    Time frame: Baseline, Weeks 52, 104 and 148

  5. 233AS101 and 233AS102 ISE: Change From Baseline in Total Amyotropic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) Score

    The ALSFRS-R measures 4 functional domains, including respiratory, bulbar function, gross motor skills, and fine motor skills. There are 12 questions, each scored from 0 (no function) to 4 (full function). The ALSFRS-R total score was calculated as the sum of the 4 functional domain scores, ranging from 0 to 48, where higher scores representing better function. Negative change from baseline indicates disease progression. This outcome measure was not a standalone analysis for 233AS102. Analysis was performed on the data collected from both 233AS101 and 233AS102 studies. This is reported as a part of the final integrated analyses. Baseline is defined as the Day 1 of 233AS101 Part C. Data has been reported for Weeks 52, 104 and 148 from the 233AS101 Part C baseline.

    Time frame: Baseline, Weeks 52, 104 and 148

  6. 233AS101 and 233AS102 ISE: Change From Baseline in Percent Predicted Slow Vital Capacity (SVC)

    Vital capacity was measured by means of an SVC test, administered in the upright position. Upright SVC was determined by performing 3 to 5 measures, in accordance with criteria established by the American Thoracic Society and the European Respiratory Society. The percent predicted SVC was calculated as \[observed SVC divided by predicted SVC\]\*100%. The predicted SVC was adjusted by sex, age, height, which was programmed into and performed by the equipment used. Negative change from baseline indicated worsening of respiratory capacity. This outcome measure was not a standalone analysis for 233AS102. Analysis was performed on the data collected from both 233AS101 and 233AS102 studies. This is reported as a part of the final integrated analyses. Baseline is defined as the Day 1 of 233AS101 Part C. Data has been reported for Weeks 52, 104 and 148 from the 233AS101 Part C baseline.

    Time frame: Baseline, Weeks 52, 104 and 148

  7. 233AS101 and 233AS102 ISE: Change From Baseline in Handheld Dynamometry (HHD) Overall Megascore

    Quantitative muscle strength was evaluated using the HHD Megascore, which tests isometric strength of multiple muscles using standard participant positioning. Approximately 8 muscle groups were examined (per each side) in both upper and lower extremities. The muscle strength values were normalized to Z scores as (post-baseline measurements - mean)/SD and averaged to provide HHD overall megascore. The overall megascore was created by averaging all eight bilateral measurement Z scores, if no more than 10 (≤ 10) measures are missing. A negative change from baseline indicated decreased muscle strength. This outcome measure was not a standalone analysis for 233AS102. Analysis was performed on the data collected from both 233AS101 and 233AS102 studies. This is reported as a part of the final integrated analyses. Baseline is defined as the Day 1 of 233AS101 Part C. Data has been reported for Weeks 52, 104 and 148 from the 233AS101 Part C baseline.

    Time frame: Baseline, Weeks 52, 104 and 148

  8. 233AS101 and 233AS102 ISE: Change From Baseline in Individual Muscle Strength Assessed by HHD

    Individual muscle strength was evaluated using handheld dynamometer which tests the isometric strength of multiple muscles using standard participant positioning. Eight muscle groups were examined (per each side) in both upper and lower extremities. Negative change from baseline=decreased muscle strength. The analyses was based on observed data. This outcome measure was not a standalone analysis for 233AS102. Analysis was performed on data collected from both 233AS101 \& 233AS102 studies. This is reported as a part of final integrated analyses.

    Time frame: Baseline, Weeks 52, 104 and 148

  9. 233AS101 and 233AS102 ISE: Time to Death or Permanent Ventilation

    Permanent ventilation was defined as ≥ 22 hours of mechanical ventilation \[invasive or noninvasive\] per day for ≥ 21 consecutive days. An event of permanent ventilation was based on an adjudicated event (i.e., adjudicated by the Endpoint Adjudication Committee (EAC) as having met the permanent ventilation criteria defined in the protocol). Time to death or permanent ventilation was defined as the time to the earliest occurrence of death or permanent ventilation. The start date for calculating time to death or permanent ventilation in days was date of first dose. Participants without an event were censored at the last known alive dates. This outcome measure was not a standalone analysis for 233AS102. Analysis was performed on data collected from both 233AS101 \& 233AS102 studies. This is reported as a part of final integrated analyses. Time to permanent ventilation or death was summarized using the Kaplan-Meier product limit method.

    Time frame: From the baseline of the study 233AS101 up to the end of the follow-up period of the current study (up to Week 364)

  10. 233AS101 and 233AS102 ISE: Time to Death

    Time to death was defined as the time from first dose received in 233AS101 to death. Participants who do not meet the endpoint definition were censored at the participant's last known alive date. Only events that were adjudicated by the EAC are included. This outcome measure was not a standalone analysis for 233AS102. Analysis was performed on data collected from both 233AS101 \& 233AS102 studies. This is reported as a part of final integrated analyses. Time to death was summarized using the Kaplan-Meier product limit method.

    Time frame: From the baseline of the study 233AS101 up to the end of the follow-up period of the current study (up to Week 364)

07

Results

Posted Aug 29, 2025

Participant flow

Participants were enrolled and took part at the investigative sites in Belgium, Canada, France, Germany, Italy, Japan, Denmark, the United Kingdom, and the United States from 08 Mar 2017 to 12 Aug 2024.

Participant flow — Overall Study
Milestone233AS101: Part C (Prior Placebo)233AS101: Part C (Prior BIIB067 100 mg)233AS101: Part A and B (All Doses)
Started326344
Completed123426
Not completed202918
Withdrew: Adverse event001
Withdrew: Lost to follow-up010
Withdrew: Consent withdrawn653
Withdrew: Investigator decision001
Withdrew: Death7145
Withdrew: Disease progression577
Withdrew: Reason not specified221

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious AEs (TESAEs)

An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE is any untoward medical occurrence that at any dose results in death, life-threatening event, requires inpatient hospitalization, significant disability/incapacity or congenital anomaly. TEAEs were defined as any AEs or SAE with an onset date and time that was on or after the first dose of study drug, or any pre-existing condition that worsened in severity after the first dose of study drug.

Time frame:
From first dose of the study drug in the current study up to end of follow-up period (up to Week 364)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious AEs (TESAEs)
Participants233AS101: Part C (Prior Placebo)233AS101: Part C (Prior BIIB067 100 mg)233AS101: Part A and B (All Doses)
TEAEs316343
TESAEs163322
SecondaryPlasma Concentration of BIIB067
Time frame:
Week 4
Reported as:
Mean · nanograms per milliliter (ng/mL)
Plasma Concentration of BIIB067
nanograms per milliliter (ng/mL)233AS101: Part C (Prior Placebo)233AS101: Part C (Prior BIIB067 100 mg)
Plasma Concentration of BIIB0671.22 ± 0.1182.05 ± 0.516
SecondaryConcentration of BIIB067 in Cerebrospinal Fluid (CSF)
Time frame:
Week 4
Reported as:
Mean · ng/mL
Concentration of BIIB067 in Cerebrospinal Fluid (CSF)
ng/mL233AS101: Part C (Prior Placebo)233AS101: Part C (Prior BIIB067 100 mg)
Concentration of BIIB067 in Cerebrospinal Fluid (CSF)19.35 ± 2.8299.18 ± 0.711
Secondary233AS101 and 233AS102 Integrated Summary of Efficacy (ISE): Total CSF Superoxide Dismutase 1 (SOD1) Protein Ratio to Baseline

This outcome measure was not a standalone analysis for 233AS102. Analysis was performed on the data collected from both 233AS101 and 233AS102 studies. This is reported as a part of the final integrated analyses. Baseline is defined as the Day 1 of 233AS101 Part C. Data has been reported for Weeks 52, 104 and 148 from the 233AS101 Part C baseline.

Time frame:
Baseline, Weeks 52, 104 and 148
Reported as:
Geometric least squares mean · ratio
233AS101 and 233AS102 Integrated Summary of Efficacy (ISE): Total CSF Superoxide Dismutase 1 (SOD1) Protein Ratio to Baseline
ratio233AS101 and 233AS102 (Part C): Placebo + Delayed-start BIIB067 100 mg233AS101 and 233AS102 (Part C): Early-start BIIB067 100 mg
Week 520.78 (0.64 to 0.96)0.67 (0.57 to 0.79)
Week 1040.81 (0.67 to 0.97)0.74 (0.65 to 0.84)
Week 1480.75 (0.61 to 0.92)0.79 (0.69 to 0.91)
Statistical analysis
  • 233AS101 and 233AS102 (Part C): Placebo + Delayed-start BIIB067 100 mg vs 233AS101 and 233AS102 (Part C): Early-start BIIB067 100 mg · Least square (ls) geometric mean ratio: 0.86 · 95% CI 0.69 to 1.08
  • 233AS101 and 233AS102 (Part C): Placebo + Delayed-start BIIB067 100 mg vs 233AS101 and 233AS102 (Part C): Early-start BIIB067 100 mg · ANCOVA · p = =0.3711 · Ls geometric mean ratio: 0.91 · 95% CI 0.75 to 1.11ANCOVA model using MI.
  • 233AS101 and 233AS102 (Part C): Placebo + Delayed-start BIIB067 100 mg vs 233AS101 and 233AS102 (Part C): Early-start BIIB067 100 mg · ANCOVA · p = =0.6344 · Ls geometric mean ratio: 1.06 · 95% CI 0.84 to 1.34ANCOVA model using MI.
Secondary233AS101 and 233AS102 ISE: Neurofilament Light Chain (NfL) Plasma Concentration Ratio to Baseline

This outcome measure was not a standalone analysis for 233AS102. Analysis was performed on the data collected from both 233AS101 and 233AS102 studies. This is reported as a part of the final integrated analyses. Baseline is defined as the Day 1 of 233AS101 Part C. Data has been reported for Weeks 52, 104 and 148 from the 233AS101 Part C baseline.

Time frame:
Baseline, Weeks 52, 104 and 148
Reported as:
Geometric least squares mean · ratio
233AS101 and 233AS102 ISE: Neurofilament Light Chain (NfL) Plasma Concentration Ratio to Baseline
ratio233AS101 and 233AS102 (Part C): Placebo + Delayed-start BIIB067 100 mg233AS101 and 233AS102 (Part C): Early-start BIIB067 100 mg
Week 520.62 (0.49 to 0.78)0.50 (0.42 to 0.60)
Week 1040.41 (0.30 to 0.55)0.33 (0.27 to 0.42)
Week 1480.36 (0.25 to 0.53)0.33 (0.26 to 0.43)
Statistical analysis
  • 233AS101 and 233AS102 (Part C): Placebo + Delayed-start BIIB067 100 mg vs 233AS101 and 233AS102 (Part C): Early-start BIIB067 100 mg · Ls geometric mean ratio: 0.8 · 95% CI 0.63 to 1.03
  • 233AS101 and 233AS102 (Part C): Placebo + Delayed-start BIIB067 100 mg vs 233AS101 and 233AS102 (Part C): Early-start BIIB067 100 mg · ANCOVA · p = =0.2306 · Ls geometric mean ratio: 0.83 · 95% CI 0.60 to 1.13ANCOVA model using MI.
  • 233AS101 and 233AS102 (Part C): Placebo + Delayed-start BIIB067 100 mg vs 233AS101 and 233AS102 (Part C): Early-start BIIB067 100 mg · ANCOVA · p = =0.6730 · Ls geometric mean ratio: 0.92 · 95% CI 0.61 to 1.38ANCOVA model using MI.
Secondary233AS101 and 233AS102 ISE: Change From Baseline in Total Amyotropic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) Score

The ALSFRS-R measures 4 functional domains, including respiratory, bulbar function, gross motor skills, and fine motor skills. There are 12 questions, each scored from 0 (no function) to 4 (full function). The ALSFRS-R total score was calculated as the sum of the 4 functional domain scores, ranging from 0 to 48, where higher scores representing better function. Negative change from baseline indicates disease progression. This outcome measure was not a standalone analysis for 233AS102. Analysis was performed on the data collected from both 233AS101 and 233AS102 studies. This is reported as a part of the final integrated analyses. Baseline is defined as the Day 1 of 233AS101 Part C. Data has been reported for Weeks 52, 104 and 148 from the 233AS101 Part C baseline.

Time frame:
Baseline, Weeks 52, 104 and 148
Reported as:
Least squares mean · score on a scale
233AS101 and 233AS102 ISE: Change From Baseline in Total Amyotropic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) Score
score on a scale233AS101 and 233AS102 (Part C): Placebo + Delayed-start BIIB067 100 mg233AS101 and 233AS102 (Part C): Early-start BIIB067 100 mg
Week 52-9.5 ± 1.46-5.9 ± 1.16
Week 104-13.1 ± 2.12-9.4 ± 1.69
Week 148-13.5 ± 2.28-9.9 ± 1.77
Statistical analysis
  • 233AS101 and 233AS102 (Part C): Placebo + Delayed-start BIIB067 100 mg vs 233AS101 and 233AS102 (Part C): Early-start BIIB067 100 mg · Least square (ls) mean difference: 3.6 · 95% CI 0.5 to 6.7
  • 233AS101 and 233AS102 (Part C): Placebo + Delayed-start BIIB067 100 mg vs 233AS101 and 233AS102 (Part C): Early-start BIIB067 100 mg · ANCOVA · p = =0.1054 · Ls mean difference: 3.7 · 95% CI -0.8 to 8.2ANCOVA model using MI.
  • 233AS101 and 233AS102 (Part C): Placebo + Delayed-start BIIB067 100 mg vs 233AS101 and 233AS102 (Part C): Early-start BIIB067 100 mg · ANCOVA · p = =0.1432 · Ls mean difference: 3.6 · 95% CI -1.2 to 8.4ANCOVA model using MI.
Secondary233AS101 and 233AS102 ISE: Change From Baseline in Percent Predicted Slow Vital Capacity (SVC)

Vital capacity was measured by means of an SVC test, administered in the upright position. Upright SVC was determined by performing 3 to 5 measures, in accordance with criteria established by the American Thoracic Society and the European Respiratory Society. The percent predicted SVC was calculated as \[observed SVC divided by predicted SVC\]\*100%. The predicted SVC was adjusted by sex, age, height, which was programmed into and performed by the equipment used. Negative change from baseline indicated worsening of respiratory capacity. This outcome measure was not a standalone analysis for 233AS102. Analysis was performed on the data collected from both 233AS101 and 233AS102 studies. This is reported as a part of the final integrated analyses. Baseline is defined as the Day 1 of 233AS101 Part C. Data has been reported for Weeks 52, 104 and 148 from the 233AS101 Part C baseline.

Time frame:
Baseline, Weeks 52, 104 and 148
Reported as:
Least squares mean · percentage of predicted volume
233AS101 and 233AS102 ISE: Change From Baseline in Percent Predicted Slow Vital Capacity (SVC)
percentage of predicted volume233AS101 and 233AS102 (Part C): Placebo + Delayed-start BIIB067 100 mg233AS101 and 233AS102 (Part C): Early-start BIIB067 100 mg
Week 52-18.7 ± 3.70-10.6 ± 2.99
Week 104-23.7 ± 5.90-14.4 ± 4.46
Week 148-18.1 ± 5.74-13.8 ± 4.07
Statistical analysis
  • 233AS101 and 233AS102 (Part C): Placebo + Delayed-start BIIB067 100 mg vs 233AS101 and 233AS102 (Part C): Early-start BIIB067 100 mg · Ls mean difference: 8.1 · 95% CI 0.3 to 15.9
  • 233AS101 and 233AS102 (Part C): Placebo + Delayed-start BIIB067 100 mg vs 233AS101 and 233AS102 (Part C): Early-start BIIB067 100 mg · ANCOVA · p = =0.0963 · Ls mean difference: 9.3 · 95% CI -1.7 to 20.4ANCOVA model using MI.
  • 233AS101 and 233AS102 (Part C): Placebo + Delayed-start BIIB067 100 mg vs 233AS101 and 233AS102 (Part C): Early-start BIIB067 100 mg · ANCOVA · p = = 0.4388 · Ls mean difference: 4.3 · 95% CI -6.6 to 15.2ANCOVA model using MI.
Secondary233AS101 and 233AS102 ISE: Change From Baseline in Handheld Dynamometry (HHD) Overall Megascore

Quantitative muscle strength was evaluated using the HHD Megascore, which tests isometric strength of multiple muscles using standard participant positioning. Approximately 8 muscle groups were examined (per each side) in both upper and lower extremities. The muscle strength values were normalized to Z scores as (post-baseline measurements - mean)/SD and averaged to provide HHD overall megascore. The overall megascore was created by averaging all eight bilateral measurement Z scores, if no more than 10 (≤ 10) measures are missing. A negative change from baseline indicated decreased muscle strength. This outcome measure was not a standalone analysis for 233AS102. Analysis was performed on the data collected from both 233AS101 and 233AS102 studies. This is reported as a part of the final integrated analyses. Baseline is defined as the Day 1 of 233AS101 Part C. Data has been reported for Weeks 52, 104 and 148 from the 233AS101 Part C baseline.

Time frame:
Baseline, Weeks 52, 104 and 148
Reported as:
Least squares mean · score on a scale
233AS101 and 233AS102 ISE: Change From Baseline in Handheld Dynamometry (HHD) Overall Megascore
score on a scale233AS101 and 233AS102 (Part C): Placebo + Delayed-start BIIB067 100 mg233AS101 and 233AS102 (Part C): Early-start BIIB067 100 mg
Week 52-0.41 ± 0.101-0.15 ± 0.079
Week 104-0.56 ± 0.154-0.42 ± 0.112
Week 148-0.43 ± 0.089-0.38 ± 0.062
Statistical analysis
  • 233AS101 and 233AS102 (Part C): Placebo + Delayed-start BIIB067 100 mg vs 233AS101 and 233AS102 (Part C): Early-start BIIB067 100 mg · Ls mean difference: 0.26 · 95% CI 0.051 to 0.477
  • 233AS101 and 233AS102 (Part C): Placebo + Delayed-start BIIB067 100 mg vs 233AS101 and 233AS102 (Part C): Early-start BIIB067 100 mg · ANCOVA · p = =0.3207 · Ls mean difference: 0.14 · 95% CI -0.141 to 0.430ANCOVA model using MI.
  • 233AS101 and 233AS102 (Part C): Placebo + Delayed-start BIIB067 100 mg vs 233AS101 and 233AS102 (Part C): Early-start BIIB067 100 mg · ANCOVA · p = =0.5452 · Ls mean difference: 0.06 · 95% CI -0.124 to 0.234ANCOVA model using MI.
Secondary233AS101 and 233AS102 ISE: Change From Baseline in Individual Muscle Strength Assessed by HHD

Individual muscle strength was evaluated using handheld dynamometer which tests the isometric strength of multiple muscles using standard participant positioning. Eight muscle groups were examined (per each side) in both upper and lower extremities. Negative change from baseline=decreased muscle strength. The analyses was based on observed data. This outcome measure was not a standalone analysis for 233AS102. Analysis was performed on data collected from both 233AS101 \& 233AS102 studies. This is reported as a part of final integrated analyses.

Time frame:
Baseline, Weeks 52, 104 and 148
Reported as:
Mean · kilogram (kg)
233AS101 and 233AS102 ISE: Change From Baseline in Individual Muscle Strength Assessed by HHD
kilogram (kg)233AS101 and 233AS102 (Part C): Placebo + Delayed-start BIIB067 100 mg233AS101 and 233AS102 (Part C): Early-start BIIB067 100 mg
Left Shoulder Flexion: Week 52-3.42 ± 6.671-0.51 ± 8.484
Left Shoulder Flexion: Week 1040.17 ± 5.714-4.16 ± 14.329
Left Shoulder Flexion: Week 148-2.48 ± 5.075-4.12 ± 8.543
Left Elbow Flexion: Week 52-3.89 ± 6.747-0.24 ± 8.031
Left Elbow Flexion: Week 104-1.26 ± 7.361-3.12 ± 13.334
Left Elbow Flexion: Week 1480.65 ± 4.560-3.33 ± 8.753
Left Wrist Extension: Week 52-3.66 ± 4.775-0.41 ± 7.170
Left Wrist Extension: Week 104-0.86 ± 5.279-1.74 ± 8.517
Left Wrist Extension: Week 1480.95 ± 5.242-2.49 ± 6.086
Left Abduction Index Finger (First Dorsal Interosseous): Week 52-0.96 ± 1.450-0.93 ± 4.448
Left Abduction Index Finger (First Dorsal Interosseous): Week 104-0.63 ± 1.266-0.62 ± 2.279
Left Abduction Index Finger (First Dorsal Interosseous): Week 148-0.41 ± 1.604-1.28 ± 4.913
Left Abduction Thumb (Abductor Pollicus Brevis): Week 52-1.15 ± 1.486-0.70 ± 2.497
Left Abduction Thumb (Abductor Pollicus Brevis): Week 104-0.69 ± 1.089-0.19 ± 2.382
Left Abduction Thumb (Abductor Pollicus Brevis): Week 148-1.10 ± 2.324-0.78 ± 3.049
Left Abduction 5th Digit (Abductor Digiti Minimi): Week 52-0.66 ± 1.208-0.49 ± 2.296
Left Abduction 5th Digit (Abductor Digiti Minimi): Week 104-0.47 ± 1.226-0.50 ± 1.999
Left Abduction 5th Digit (Abductor Digiti Minimi): Week 148-0.43 ± 1.496-0.66 ± 2.394
Left Knee Extension: Week 52-4.94 ± 8.0151.80 ± 10.744
Left Knee Extension: Week 104-2.41 ± 6.545-1.54 ± 13.222
Left Knee Extension: Week 148-2.48 ± 7.339-2.01 ± 9.711
Left Ankle Dorsiflexion: Week 52-2.82 ± 7.5600.72 ± 7.701
Left Ankle Dorsiflexion: Week 104-5.47 ± 3.590-4.20 ± 11.516
Left Ankle Dorsiflexion: Week 148-5.43 ± 5.303-2.33 ± 9.533
Right Shoulder Flexion: Week 52-4.74 ± 5.494-0.96 ± 5.728
Right Shoulder Flexion: Week 104-2.72 ± 4.638-2.81 ± 9.304
Right Shoulder Flexion: Week 148-3.02 ± 5.066-3.18 ± 8.139
Right Elbow Flexion: Week 52-4.03 ± 5.663-1.20 ± 7.015
Right Elbow Flexion: Week 104-1.32 ± 6.289-3.04 ± 9.717
Right Elbow Flexion: Week 1480.49 ± 3.407-3.28 ± 8.704
Right Wrist Extension: Week 52-3.82 ± 5.892-0.63 ± 4.870
Right Wrist Extension: Week 104-0.76 ± 4.086-1.65 ± 6.267
Right Wrist Extension: Week 1480.09 ± 5.096-1.89 ± 5.033
Right Abduction Index Finger (First Dorsal Interosseous): Week 52-0.86 ± 1.381-0.36 ± 1.405
Right Abduction Index Finger (First Dorsal Interosseous): Week 104-0.38 ± 1.057-0.45 ± 1.569
Right Abduction Index Finger (First Dorsal Interosseous): Week 148-0.23 ± 1.545-0.46 ± 1.193
Right Abduction Thumb (Abductor Pollicus Brevis): Week 52-0.98 ± 1.425-1.24 ± 4.595
Right Abduction Thumb (Abductor Pollicus Brevis): Week 104-0.31 ± 0.947-0.24 ± 2.016
Right Abduction Thumb (Abductor Pollicus Brevis): Week 148-0.86 ± 1.861-1.10 ± 5.247
Right Abduction 5th Digit (Abductor Digiti Minimi): Week 52-0.78 ± 1.210-1.12 ± 5.112
Right Abduction 5th Digit (Abductor Digiti Minimi): Week 104-0.54 ± 1.059-0.21 ± 1.639
Right Abduction 5th Digit (Abductor Digiti Minimi): Week 148-0.69 ± 1.009-1.36 ± 5.634
Right Knee Extension: Week 52-4.90 ± 5.9641.05 ± 8.973
Right Knee Extension: Week 104-2.16 ± 9.453-3.09 ± 13.046
Right Knee Extension: Week 148-0.19 ± 7.407-1.60 ± 7.685
Right Ankle Dorsiflexion: Week 52-5.68 ± 8.907-1.05 ± 5.923
Right Ankle Dorsiflexion: Week 104-5.86 ± 3.501-3.78 ± 13.008
Right Ankle Dorsiflexion: Week 148-6.74 ± 7.308-3.40 ± 8.172
Secondary233AS101 and 233AS102 ISE: Time to Death or Permanent Ventilation

Permanent ventilation was defined as ≥ 22 hours of mechanical ventilation \[invasive or noninvasive\] per day for ≥ 21 consecutive days. An event of permanent ventilation was based on an adjudicated event (i.e., adjudicated by the Endpoint Adjudication Committee (EAC) as having met the permanent ventilation criteria defined in the protocol). Time to death or permanent ventilation was defined as the time to the earliest occurrence of death or permanent ventilation. The start date for calculating time to death or permanent ventilation in days was date of first dose. Participants without an event were censored at the last known alive dates. This outcome measure was not a standalone analysis for 233AS102. Analysis was performed on data collected from both 233AS101 \& 233AS102 studies. This is reported as a part of final integrated analyses. Time to permanent ventilation or death was summarized using the Kaplan-Meier product limit method.

Time frame:
From the baseline of the study 233AS101 up to the end of the follow-up period of the current study (up to Week 364)
Reported as:
Median · weeks
233AS101 and 233AS102 ISE: Time to Death or Permanent Ventilation
weeks233AS101 and 233AS102 (Part C): Placebo + Delayed-start BIIB067 100 mg233AS101 and 233AS102 (Part C): Early-start BIIB067 100 mg
233AS101 and 233AS102 ISE: Time to Death or Permanent VentilationNA (135.6 to NA)NA (253.6 to NA)
Statistical analysis
  • 233AS101 and 233AS102 (Part C): Placebo + Delayed-start BIIB067 100 mg vs 233AS101 and 233AS102 (Part C): Early-start BIIB067 100 mg · Log Rank · p = =0.4202 · Hazard ratio (hr): 0.64 · 95% CI 0.282 to 1.461The analysis was based on a Cox proportional hazards model adjusted for baseline plasma NfL, and riluzole or edaravone use.
Secondary233AS101 and 233AS102 ISE: Time to Death

Time to death was defined as the time from first dose received in 233AS101 to death. Participants who do not meet the endpoint definition were censored at the participant's last known alive date. Only events that were adjudicated by the EAC are included. This outcome measure was not a standalone analysis for 233AS102. Analysis was performed on data collected from both 233AS101 \& 233AS102 studies. This is reported as a part of final integrated analyses. Time to death was summarized using the Kaplan-Meier product limit method.

Time frame:
From the baseline of the study 233AS101 up to the end of the follow-up period of the current study (up to Week 364)
Reported as:
Median · weeks
233AS101 and 233AS102 ISE: Time to Death
weeks233AS101 and 233AS102 (Part C): Placebo + Delayed-start BIIB067 100 mg233AS101 and 233AS102 (Part C): Early-start BIIB067 100 mg
233AS101 and 233AS102 ISE: Time to DeathNA (NA to NA)NA (260.7 to NA)
Statistical analysis
  • 233AS101 and 233AS102 (Part C): Placebo + Delayed-start BIIB067 100 mg vs 233AS101 and 233AS102 (Part C): Early-start BIIB067 100 mg · Log Rank · p = =0.3108 · Hazard ratio (hr): 0.52 · 95% CI 0.199 to 1.357The analysis was based on a Cox proportional hazards model adjusted for baseline plasma NfL, and riluzole or edaravone use.

Adverse events

Collected over From first dose of the study drug in the current study up to end of follow-up period (up to Week 364). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
233AS101: Part C (Prior Placebo)7/32 (21.9%)16/32 (50%)31/32 (96.9%)
233AS101: Part C (Prior BIIB067 100 mg)14/63 (22.2%)33/63 (52.4%)63/63 (100%)
233AS101: Parts A and B (All Doses)5/44 (11.4%)22/44 (50%)43/44 (97.7%)
Most frequent serious events
Showing 10 of 86
Most frequent serious events
Event233AS101: Part C (Prior Placebo)233AS101: Part C (Prior BIIB067 100 mg)233AS101: Parts A and B (All Doses)
Respiratory failureRespiratory, thoracic and mediastinal disorders6/326/635/44
Pneumonia aspirationInfections and infestations3/328/632/44
DysphagiaGastrointestinal disorders1/327/633/44
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/326/630/44
FallInjury, poisoning and procedural complications0/321/634/44
ConstipationGastrointestinal disorders2/320/630/44
PneumoniaInfections and infestations2/322/631/44
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/321/632/44
Respiratory distressRespiratory, thoracic and mediastinal disorders0/320/632/44
Cardiac arrestCardiac disorders1/322/630/44
Most frequent other events
Showing 10 of 132
Most frequent other events
Event233AS101: Part C (Prior Placebo)233AS101: Part C (Prior BIIB067 100 mg)233AS101: Parts A and B (All Doses)
HeadacheNervous system disorders17/3235/6331/44
FallInjury, poisoning and procedural complications18/3225/6328/44
Procedural painInjury, poisoning and procedural complications14/3233/6328/44
Back painMusculoskeletal and connective tissue disorders14/3227/6326/44
NasopharyngitisInfections and infestations6/3211/6320/44
Pain in extremityMusculoskeletal and connective tissue disorders12/3217/6319/44
Covid-19Infections and infestations7/3226/6313/44
NauseaGastrointestinal disorders7/3213/6317/44
ArthralgiaMusculoskeletal and connective tissue disorders12/3219/6317/44
DiarrhoeaGastrointestinal disorders12/327/637/44

Baseline characteristics

The safety population included all participants who were enrolled and received at least one dose of study treatment in 233AS102.

Age, Continuous
Age, Continuous(years)233AS101: Part C (Prior Placebo)233AS101: Part C (Prior BIIB067 100 mg)233AS101: Part A and B (All Doses)Total
Mean52.8 ± 11.0048.1 ± 11.8049.8 ± 11.0449.7 ± 11.45
Sex: Female, Male
Sex: Female, Male(Participants)233AS101: Part C (Prior Placebo)233AS101: Part C (Prior BIIB067 100 mg)233AS101: Part A and B (All Doses)Total
Female15241958
Male17392581
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)233AS101: Part C (Prior Placebo)233AS101: Part C (Prior BIIB067 100 mg)233AS101: Part A and B (All Doses)Total
Hispanic or Latino1304
Not Hispanic or Latino25402691
Unknown or Not Reported6201844
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)233AS101: Part C (Prior Placebo)233AS101: Part C (Prior BIIB067 100 mg)233AS101: Part A and B (All Doses)Total
Race — American Indian or Alaska Native0000
Race — Asian4419
Race — Black or African American0101
Race — Native Hawaiian or Other Pacific Islander0011
Race — White22372382
Race — Not Reported6201844
Race — Other0112
08

Study locations

30 sites
  • Research Site
    Phoenix, Arizona 85013, United States
  • Research Site
    La Jolla, California 92093-0949, United States
  • Research Site
    San Francisco, California 94118, United States
  • Research Site
    Jacksonville, Florida 32224, United States
  • Research Site
    Miami, Florida 33136, United States
  • Research Site
    Orlando, Florida 32806, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Chicago, Illinois 60611, United States
  • Research Site
    Baltimore, Maryland 21287, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    St Louis, Missouri 63110, United States
  • Research Site
    Lincoln, Nebraska 68510, United States
  • Research Site
    Cleveland, Ohio 44106, United States
  • Research Site
    Portland, Oregon 97213, United States
  • Research Site
    Knoxville, Tennessee 37920, United States
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Calgary, Alberta T2N 4Z6, Canada
  • Research Site
    Edmonton, Alberta T6G 2B7, Canada
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
  • Research Site
    Montreal, Quebec H3A2B4, Canada
  • Bispebjerg Hospital
    Copenhagen, 2400, Denmark
  • Research Site
    Clermont-Ferrand, Puy De Dome 63003, France
  • Research Site
    Ulm, Baden-Wurttemberg 89081, Germany
  • Research Site
    Torino, 10126, Italy
  • Research Site
    Bunkyō City, Japan
  • Research Site
    Kagoshima, Japan
  • Research Site
    Shinjuku-ku, Japan
  • Research Site
    Suita-shi, Japan
  • Research Site
    Sheffield, South Yorkshire S102HQ, United Kingdom
09

References and documents

Publications

  • Miller TM, Cudkowicz ME, Shaw PJ, Genge A, Sobue G, Bucelli RC, Chio A, Van Damme P, Ludolph AC, Glass JD, Andrews JA, Babu S, Benatar M, McDermott CJ, Salachas F, Bruneteau G, Al-Chalabi A, Amorin M, Nestorov I, Graham D, Lin L, Sun P, McNeill M, Malek S, Inra J, Garafalo S, Fradette S; VALOR and OLE Working Group. Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis. JAMA Neurol. 2026 Feb 1;83(2):115-125. doi: 10.1001/jamaneurol.2025.4946. PubMed 41661214 ↗
  • Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, Chio A, Van Damme P, Ludolph AC, Glass JD, Andrews JA, Babu S, Benatar M, McDermott CJ, Cochrane T, Chary S, Chew S, Zhu H, Wu F, Nestorov I, Graham D, Sun P, McNeill M, Fanning L, Ferguson TA, Fradette S; VALOR and OLE Working Group. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2022 Sep 22;387(12):1099-1110. doi: 10.1056/NEJMoa2204705. PubMed 36129998 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Aug 2024, 89 months.

Results were first posted in Aug 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2017
First posted
Mar 3, 2017
StartActual
Mar 8, 2017
Primary completionActual
Aug 12, 2024
CompletionActual
Aug 12, 2024
Results first posted
Aug 29, 2025
Last update
Aug 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03070119
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Mar 3, 2017
Start date
Mar 8, 2017
Primary completion
Aug 12, 2024
Completion
Aug 12, 2024
Results posted
Aug 29, 2025
Last update
Aug 29, 2025

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofersen

Start the discussion